254 related articles for article (PubMed ID: 37878624)
1. GPC-100, a novel CXCR4 antagonist, improves in vivo hematopoietic cell mobilization when combined with propranolol.
Sukhtankar DD; Fung JJ; Kim MN; Cayton T; Chiou V; Caculitan NG; Zalicki P; Kim S; Jo Y; Kim S; Lee JM; Choi J; Mun S; Chin A; Jang Y; Lee JY; Kim G; Kim EH; Huh WK; Jeong JY; Seen DS; Cardarelli PM
PLoS One; 2023; 18(10):e0287863. PubMed ID: 37878624
[TBL] [Abstract][Full Text] [Related]
2. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.
Nademanee AP; DiPersio JF; Maziarz RT; Stadtmauer EA; Micallef IN; Stiff PJ; Hsu FJ; Bridger G; Bolwell BJ
Biol Blood Marrow Transplant; 2012 Oct; 18(10):1564-72. PubMed ID: 22683613
[TBL] [Abstract][Full Text] [Related]
3. Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma.
Steinberg M; Silva M
Clin Ther; 2010 May; 32(5):821-43. PubMed ID: 20685493
[TBL] [Abstract][Full Text] [Related]
4. The CXCR4 and adhesion molecule expression of CD34+ hematopoietic cells mobilized by "on-demand" addition of plerixafor to granulocyte-colony-stimulating factor.
Girbl T; Lunzer V; Greil R; Namberger K; Hartmann TN
Transfusion; 2014 Sep; 54(9):2325-35. PubMed ID: 24673458
[TBL] [Abstract][Full Text] [Related]
5. Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells.
Uy GL; Rettig MP; Cashen AF
Expert Opin Biol Ther; 2008 Nov; 8(11):1797-804. PubMed ID: 18847313
[TBL] [Abstract][Full Text] [Related]
6. Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma.
Keating GM
Drugs; 2011 Aug; 71(12):1623-47. PubMed ID: 21861545
[TBL] [Abstract][Full Text] [Related]
7. Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program.
Worel N; Rosskopf K; Neumeister P; Kasparu H; Nachbaur D; Russ G; Namberger K; Witt V; Schloegl E; Zojer N; Linkesch W; Kalhs P; Greinix HT
Transfusion; 2011 May; 51(5):968-75. PubMed ID: 20880037
[TBL] [Abstract][Full Text] [Related]
8. [Efficiency and safety analysis of Plerixafor combined with granulocyte colony-stimulating factor on autologous hematopoietic stem cell mobilization in lymphoma].
Ji MM; Shen YG; Gong JC; Tang W; Xu XQ; Zheng Z; Chen SY; He Y; Zheng X; Zhao LD; Zhao WL; Wu W
Zhonghua Xue Ye Xue Za Zhi; 2023 Feb; 44(2):112-117. PubMed ID: 36948864
[No Abstract] [Full Text] [Related]
9. Stimulation of adrenergic activity by desipramine enhances hematopoietic stem and progenitor cell mobilization along with G-CSF in multiple myeloma: A pilot study.
Shastri A; Budhathoki A; Barta SK; Kornblum N; Derman O; Battini R; Raghupathy R; Verma AK; Frenette PS; Braunschweig I; Janakiram M
Am J Hematol; 2017 Oct; 92(10):1047-1051. PubMed ID: 28675459
[TBL] [Abstract][Full Text] [Related]
10. Plerixafor: a peripheral blood stem cell mobilizer.
Kessans MR; Gatesman ML; Kockler DR
Pharmacotherapy; 2010 May; 30(5):485-92. PubMed ID: 20411999
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics.
Li J; Hamilton E; Vaughn L; Graiser M; Renfroe H; Lechowicz MJ; Langston A; Prichard JM; Anderson D; Gleason C; Lonial S; Flowers CR; Kaufman JL; Waller EK
Transfusion; 2011 Oct; 51(10):2175-82. PubMed ID: 21492180
[TBL] [Abstract][Full Text] [Related]
12. Effective mobilization of hematopoietic progenitor cells in G-CSF mobilization defective CD26-/- mice through AMD3100-induced disruption of the CXCL12-CXCR4 axis.
Paganessi LA; Walker AL; Tan LL; Holmes I; Rich E; Fung HC; Christopherson KW
Exp Hematol; 2011 Mar; 39(3):384-90. PubMed ID: 21168468
[TBL] [Abstract][Full Text] [Related]
13. Successful Mobilization of Autologous Hematopoietic Peripheral Blood Stem Cells after Salvage Chemotherapy in Patients with Low CD34 Blood Cell Counts.
Holmberg LA; Linenberger M; Connelly-Smith L
Transplant Cell Ther; 2022 Nov; 28(11):754-759. PubMed ID: 36002104
[TBL] [Abstract][Full Text] [Related]
14. Additional plerixafor to granulocyte colony-stimulating factors for haematopoietic stem cell mobilisation for autologous transplantation in people with malignant lymphoma or multiple myeloma.
Hartmann T; Hübel K; Monsef I; Engert A; Skoetz N
Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD010615. PubMed ID: 26484982
[TBL] [Abstract][Full Text] [Related]
15. Plerixafor (Mozobil) alone to mobilize hematopoietic stem cells from multiple myeloma patients for autologous transplantation.
Flomenberg N; Comenzo RL; Badel K; Calandra G
Biol Blood Marrow Transplant; 2010 May; 16(5):695-700. PubMed ID: 20067838
[TBL] [Abstract][Full Text] [Related]
16. Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial.
Crees ZD; Rettig MP; Jayasinghe RG; Stockerl-Goldstein K; Larson SM; Arpad I; Milone GA; Martino M; Stiff P; Sborov D; Pereira D; Micallef I; Moreno-Jiménez G; Mikala G; Coronel MLP; Holtick U; Hiemenz J; Qazilbash MH; Hardy N; Latif T; García-Cadenas I; Vainstein-Haras A; Sorani E; Gliko-Kabir I; Goldstein I; Ickowicz D; Shemesh-Darvish L; Kadosh S; Gao F; Schroeder MA; Vij R; DiPersio JF
Nat Med; 2023 Apr; 29(4):869-879. PubMed ID: 37069359
[TBL] [Abstract][Full Text] [Related]
17. The high-affinity CXCR4 antagonist BKT140 is safe and induces a robust mobilization of human CD34+ cells in patients with multiple myeloma.
Peled A; Abraham M; Avivi I; Rowe JM; Beider K; Wald H; Tiomkin L; Ribakovsky L; Riback Y; Ramati Y; Aviel S; Galun E; Shaw HL; Eizenberg O; Hardan I; Shimoni A; Nagler A
Clin Cancer Res; 2014 Jan; 20(2):469-79. PubMed ID: 24246358
[TBL] [Abstract][Full Text] [Related]
18. FDA review summary: Mozobil in combination with granulocyte colony-stimulating factor to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation.
Brave M; Farrell A; Ching Lin S; Ocheltree T; Pope Miksinski S; Lee SL; Saber H; Fourie J; Tornoe C; Booth B; Yuan W; He K; Justice R; Pazdur R
Oncology; 2010; 78(3-4):282-8. PubMed ID: 20530974
[TBL] [Abstract][Full Text] [Related]
19. [Mobilization of peripheral blood stem cells with plerixafor in poor mobilizer patients].
Sancho JM; Duarte R; Medina L; Querol S; Marín P; Sureda A;
Med Clin (Barc); 2016 Sep; 147(5):223.e1-223.e7. PubMed ID: 27374031
[TBL] [Abstract][Full Text] [Related]
20. Characterization of hematopoietic stem cell subsets from patients with multiple myeloma after mobilization with plerixafor.
Taubert I; Saffrich R; Zepeda-Moreno A; Hellwig I; Eckstein V; Bruckner T; Ho AD; Wuchter P
Cytotherapy; 2011 Apr; 13(4):459-66. PubMed ID: 21077729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]